Vimarsana
Biggest News Aggregation in the World

Page 2 - Lung Fact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lung Fact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lung Fact Today - Breaking & Trending Today

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial - Vimarsana News

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

Published: October 23, 2023

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors Datopotamab...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomSusan GalbraithAaron LisbergDaiichi SankyoKen TakeshitaAnn OncSapporo Medical UniversityAmerican Cancer SocietyInternational Agency For Research On CancerWorld Health OrganizationNational Cancer InstituteLung Ambition AllianceEuropean Society For Medical OncologyAnticancer ResearchCongress OnPresidential SymposiumEuropean SocietyMedical OncologyThoracic Medical OncologyExecutive Vice PresidentGlobal HeadNorth AmericaRare DiseasesStatistics Factsheets
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer - Vimarsana News

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

Published: October 16, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--

Source: eagletribune.com
Related Topics:
United KingdomUnited StatesSusan GalbraithBrendan McevoyDaiichi SankyoChelsea FordWorld Health OrganisationInternational Agency For Research On CancerLungevity FoundationSingle Institution StudyLung Ambition AllianceDrug AdministrationNew Drug ApplicationPriority ReviewPrescription Drug User Fee ActExecutive Vice PresidentPresidential SymposiumInternational AssociationLung CancerPrescription InformationPatient InformationSouth AmericaRare DiseasesAccessed SeptemberInternational Agency
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial - Vimarsana News

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Published: September 11, 2023

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesDaiichi SankyoSingle Institution StudyLung Ambition AllianceCompany On Social Media AstrazenecaLungevity FoundationWorld Health OrganisationInternational Agency For Research On CancerPresidential SymposiumInternational AssociationLung CancerPrescribing InformationPatient InformationSouth AmericaRare DiseasesSocial MediaInternational AgencyLung FactAccessed AugustSmall CellHistological SamplesNon Small Cell Lung CancerSystematic ReviewIntj Clin Exp
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial - Vimarsana News

Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial

Published: September 10, 2023

An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients BLA submission in U.S. planned for the second half of fiscal year 2023 ...

Source: marketscreener.com
Related Topics:
United StatesHelena YuKen TakeshitaDaiichi SankyoPatritumab DeruxtecanInternational Agency For Research On CancerMemorial Sloan Kettering Cancer CenterWorld Health OrganizationLung CancerAssociate Attending PhysicianMemorial Sloan Kettering CancerGlobal HeadNorth AmericaMutated Non Small Cell Lung CancerBreakthrough Therapy DesignationDrug AdministrationInternational AgencyLung FactAccessed JanuaryEnglj Med
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial - Vimarsana News

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Published: July 3, 2023

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jul 3, 2023--

Source: valdostadailytimes.com
Related Topics:
United StatesJennifer BrennanSusan GalbraithKen TakeshitaAnn OncKoji OgiwaraDaiichi SankyoDaiichi Sankyo Co LtdDaiichi Sankyo IncAnticancer ResearchInternational Agency For Research On CancerSapporo Medical UniversityAmerican Cancer SocietySarah Cannon Research InstituteWorld Health OrganizationGlobal HeadExecutive Vice PresidentNorth AmericaDatopotamab DeruxtecanSarah Cannon ResearchInternational AgencyLung FactAccessed JuneTargeted Drug TherapyNon Small Cell Lung